COVID-19 Treatment (FM203) Selection of Preclinical Test Support Project for Infectious Diseases

Glaucoma Treatment (FM101) Selection of the National New Drug Development Project (KDDF) New Drug Clinical Development Research Project

The Ministry of SMEs and Startups selected a 'preliminary unicorn'


Evaluation A and A grades of technology growth companies (Korea Industrial Technology Evaluation Management Agency, Nice Evaluation Information)

FM101 Approves Phase 2 IND For NASH Indication (Europe)

[Ascentage Pharma (Hong Kong-listed corporation)] NASH Joint Research Agreement Signed

FM101 Approves Phase 2 IND For Glaucoma Indication (Australia)

FM101, designated by the U.S. Food and Drug Administration (FDA) as a rare drug for 'primary bile ductitis'

PPre-IPO investment attraction of 7.2 billion completed (Raguna Investment, Korea Asset Investment & Securities, etc.)

The Ministry of Science and ICT selected a project to develop an innovative new drug pipeline

  • - Metabolic anticancer drugs for the development of innovative new drug pipelines (2 years, 2 billion won in project
  • - Targeted anticancer drugs for the development of innovative new drug pipelines (2 years, 3 billion won in project cost)

[Dongkuk University, Korea Biotechnology Research Institute] Signed a contract for a metabolic anticancer drug, License-In

Future Medicine Establishes Australian Corporation

FM101, License-Out (Domestic and China) to HK Innoen (formerly CJ Healthcare Co., Ltd.)

Selection of non-clinical tasks by the Ministry of Health and Welfare: Non-clinical support for COVID-19 treatments (1 year, project cost KRW 640 million)

[SNU Industry-Academic Cooperation Group] Know-how related to immuno-cancer drugs signed a license-in contract

Ministry of Health and Welfare's Health and Medical Technology R&D Project Selection: NASH Treatment Development (2 years, project cost KRW 2.1 billion)

Pre-IPO attracting 6.5 billion investment (Korea Investment & Securities, Hanwha Investment & Securities, HK Innoen, BNK Venture Investment)


FM101 End of Phase 1 Clinical Trials in Europe

[Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation Drug Production Center] Signed a contract to produce GMP reagents for FM101 Phase 2 clinical trials

[Dongkuk University College of Pharmacy] MoU signed for joint development of new drug candidate materials

[CJ Healthcare Co., Ltd.] Signed a joint research contract to develop new drug candidates for immuno-cancer

Series B 7 billion (convertible bonds) investment attraction (Kolon Investment, Wooshin Venture Investment, NH Investment & Securities, etc.)

FM101 Study Selected Outstanding Green for 2019 European Liver Association Conference

[Korea Research Institute of Chemistry] FM501 Signed a joint R&D contract for autoimmune disease treatment

Innovative Small and Medium Business (INNOBIZ) certification


FM101 EMA Approves Phase 1 Clinical Trial

6.1 billion Series A investment attraction (Kolon Investment, Wooshin Venture Investment, etc.)

Diabetic nephropathy efficacy data Nature sister magazine EMM journal published

Patent registration of pharmaceutical compositions for the prevention and treatment of chronic kidney diseases including adenosine derivatives


FM101 Patent registration for glaucoma treatment

NASH Selection of Non-Clinical/Clinical Tasks by the Ministry of Health and Welfare

FM101 Patent registration for non-alcoholic steatohepatitis (NASH) treatment

2016 ~ 2015

[Seoul National University Industry-Academic Cooperation Group] Signed a joint research service contract for new drug candidates

Certification of venture companies

Is it authorized to establish a new drug development research institute affiliated with a company

FM Therapeutics merger

Future Medicine Inc. Established Medicine Inc